Next Article in Journal
Functional Analysis of Long Non-Coding RNAs Reveal Their Novel Roles in Biocontrol of Bacteria-Induced Tomato Resistance to Meloidogyne incognita
Next Article in Special Issue
Targeting High Mobility Group Box 1 in Subarachnoid Hemorrhage: A Systematic Review
Previous Article in Journal
Molecular Imaging of Pulmonary Inflammation and Infection
Previous Article in Special Issue
High Mobility Group A (HMGA): Chromatin Nodes Controlled by a Knotty miRNA Network

High-Mobility Group Box 1 Protein Signaling in Painful Diabetic Neuropathy

Department of Molecular and Translational Medicine, Center of Emphasis in Diabetes and Metabolism, Texas Tech University Health Sciences Center El Paso, El Paso, TX 79912, USA
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(3), 881;
Received: 25 November 2019 / Revised: 15 January 2020 / Accepted: 25 January 2020 / Published: 30 January 2020
(This article belongs to the Special Issue HMG Proteins in Development and Disease)
Diabetes is a global epidemic and more than 50% diabetic patients are also diagnosed with neuropathy, which greatly affects the quality of life of the patients. Available treatments are not always successful due to the limited efficacy and complications, such as addiction and dependency. Studies have implicated that high mobility group box1 (HMGB1) protein plays a crucial role in neuroinflammation and the development of neuropathic conditions. HMGB1 is a proinflammatory cytokine that can be released from necrotic cells in passive form or in response to inflammatory signals as an active form. HMGB1 is the ligand for the receptor for advanced glycation end products (RAGE), and toll-like receptors, (TLR)-2 and TLR4, which also indirectly activates C-X-C chemokine receptor type 4 (CXCR4). We investigated whether blocking of HMGB1 can reduce pain and inflammation in diabetic neuropathic animals to further understand the role of HMGB1 in diabetic neuropathy. Type 2 diabetic rats and mice were treated with natural inhibitor of HMGB1, glycyrrhizin (GLC) for five days/week for four weeks at a dose of 50 mg/kg per day by intraperitoneal injection. The animals were divided into three categories: naïve control, diabetic alone, diabetic with GLC treatment. All of the behavioral analyses were conducted before and after the treatment. The expression of inflammatory markers and changes in histone acetylation in the peripheral nervous system were measured by immunohistochemistry and Western blot analysis after the completion of the treatment. Our study revealed that TLR4, HMGB1, CXCR4, and Nod-like receptor protein 3 (NLRP3) levels were increased in the spinal and dorsal root ganglia (DRG) neurons of Type 2 diabetic mice and rats with painful neuropathy. GLC treatment inhibited the increases in TLR4, NLRP3, and CXCR4 expressions and improved the mechanical and thermal pain threshold in these animals. Immunohistochemical studies revealed that hyperglycemia mediated inflammation influenced HMGB1 acetylation and its release from the neurons. It also altered histone 3 acetylation in the microglial cells. The inhibition of HMGB1 by GLC prevented the release of HMGB1 as well as H3K9 acetylation. These findings indicate that the interruption of HMGB1 mediated inflammation could ameliorate diabetic neuropathy and might exhibit a unique target for the treatment. View Full-Text
Keywords: Diabetes; neuropathy; high mobility group box1 (HMGB1); inflammation; neuropathy; glycyrrhizin Diabetes; neuropathy; high mobility group box1 (HMGB1); inflammation; neuropathy; glycyrrhizin
Show Figures

Graphical abstract

MDPI and ACS Style

Thakur, V.; Sadanandan, J.; Chattopadhyay, M. High-Mobility Group Box 1 Protein Signaling in Painful Diabetic Neuropathy. Int. J. Mol. Sci. 2020, 21, 881.

AMA Style

Thakur V, Sadanandan J, Chattopadhyay M. High-Mobility Group Box 1 Protein Signaling in Painful Diabetic Neuropathy. International Journal of Molecular Sciences. 2020; 21(3):881.

Chicago/Turabian Style

Thakur, Vikram, Jayanarayanan Sadanandan, and Munmun Chattopadhyay. 2020. "High-Mobility Group Box 1 Protein Signaling in Painful Diabetic Neuropathy" International Journal of Molecular Sciences 21, no. 3: 881.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop